Vaxart, Inc.
VXRT · OTCMCIK 72444fmd_10AKX9R1E8W8R585K4ZPTKCZHRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Dec 28, 2008 to Sep 30, 2026, 69 periods
Latest annual · FY2025
Millions- Total revenues
- 237
- Operating income
- 18
- Net income
- 16
- Free cash flow
- 8
Latest quarter · Q3 FY2026
Millions- Total revenues
- 11
- Operating income
- (17)
- Net income
- (18)
- Free cash flow
- 1
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +1,204.0%
- Revenue, 5 yearsFY2020 to FY2025
- +125.8%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Vaxart, Inc. (VXRT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $237.3 million | $28.7 million | +726.7% | 10-K 2026-03-13 · proof |
| Operating income | $18.1 million | -$66.3 million | 10-K 2026-03-13 · proof | |
| Net income | $16.3 million | -$66.9 million | 10-K 2026-03-13 · proof | |
| Cash from operating activities | $7.7 million | -$44.8 million | 10-K 2026-03-13 · proof | |
| Free cash flow | $7.6 million | -$45.3 million | 10-K 2026-03-13 · proof | |
| Total assets | $186.1 million | $166.4 million | +11.8% | 10-K 2026-03-13 · proof |
| Total liabilities | $98.3 million | $107.5 million | -8.5% | 10-K 2026-03-13 · proof |
| Cash and cash equivalents | $53.8 million | $25.2 million | +113.3% | 10-K 2026-03-13 · proof |
- What was Vaxart, Inc. (VXRT)'s revenue in fiscal 2025?
- Vaxart, Inc. (VXRT) reported revenue of $237.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $28.7 million the year before (+726.7%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What was Vaxart, Inc. (VXRT)'s operating income in fiscal 2025?
- Vaxart, Inc. (VXRT) reported operating income of $18.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$66.3 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What was Vaxart, Inc. (VXRT)'s net income in fiscal 2025?
- Vaxart, Inc. (VXRT) reported net income of $16.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$66.9 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What was Vaxart, Inc. (VXRT)'s cash from operating activities in fiscal 2025?
- Vaxart, Inc. (VXRT) reported cash from operating activities of $7.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$44.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What was Vaxart, Inc. (VXRT)'s free cash flow in fiscal 2025?
- Vaxart, Inc. (VXRT) reported free cash flow of $7.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$45.3 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What are Vaxart, Inc. (VXRT)'s total assets?
- As of Dec 31, 2025, Vaxart, Inc. (VXRT) reported total assets of $186.1 million, against $166.4 million a year earlier (+11.8%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What are Vaxart, Inc. (VXRT)'s total liabilities?
- As of Dec 31, 2025, Vaxart, Inc. (VXRT) reported total liabilities of $98.3 million, against $107.5 million a year earlier (-8.5%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
- What are Vaxart, Inc. (VXRT)'s cash and cash equivalents?
- As of Dec 31, 2025, Vaxart, Inc. (VXRT) reported cash and cash equivalents of $53.8 million, against $25.2 million a year earlier (+113.3%). Source: the 10-K filed with the SEC on Mar 13, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:VXRT&period_type=annual&limit=5"Information only, not investment advice.